Tempest Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 19, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 19, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| TEMPEST THERAPEUTICS, INC. | |
|---|---|
| By: | /s/ Stephen Brady |
| Stephen Brady | |
| Chief Executive Officer & President (Principal Executive Officer) | |
| By: | /s/ Nicholas Maestas |
| Nicholas Maestas | |
| Vice-President, Strategy and Finance (Principal Financial Officer) | |
Date: March 19, 2024
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Stephen Bradyand Nicolas Maestas, jointly and severally, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign this Annual Report on Form 10-K of Tempest Therapeutics, Inc., and any or all amendments thereto, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises hereby ratifying and confirming all that said attorneys-in-fact and agents, or his, her or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Stephen Brady | Chief Executive Officer, President and Director (Principal Executive Officer) | March 19, 2024 |
| Stephen Brady | ||
| /s/ Nicholas Maestas | Vice President, Strategy and Finance and Secretary(Principal Financial Officer) | March 19, 2024 |
| Nicholas Maestas | ||
| /s/ Justin Trojanowski | Corporate Controller, Treasurer(Principal Accounting Officer) | March 19, 2024 |
| Justin Trojanowski | ||
| /s/ Michael Raab | Chairman of the Board of Directors | March 19, 2024 |
| Michael Raab | ||
| /s/ Geoff Nichol | Director | March 19, 2024 |
| Geoff Nichol, M.B., Ch.B., M.B.A. | ||
| /s/ Christine Pellizzari | Director | March 19, 2024 |
| Christine Pellizzari | ||
| /s/ Ronit Simantov | Director | March 19, 2024 |
| Ronit Simantov, M.D. | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.